Abstract
The present study was designed to investigate whether the neuroprotective effect of nimesulide was mediated by inhibiting expression of matrix metalloproteinase-9 (MMP-9) and/or matrix metalloproteinase-2 (MMP-2) in a rat model of thrombolytic reperfusion after the embolic focal cerebral ischemia (FCI). It was found that nimesulide at therapeutically relevant doses (3, 6 and 12 mg/kg) decreased neurological deficits, infarct volume, brain index and brain water content in a dose-dependent manner. Hemorrhagic transformation was reduced by 64% with treatment of 12 mg/kg nimesulide. Quantitative analysis of immunohistochemical staining of brain slices showed that the neuron number expressing MMP-9 and MMP-2 increased in the model animals treated with vehicle (p < 0.01 vs sham group), and significantly decreased in nimesulide-treated animals (p < 0.05 or p < 0.01 vs vehicle group). Our results demonstrate that nimesulide significantly reduces the degree of neuronal injury and hemorrhage transformation caused by thrombolytic reperfusion after the embolic FCI, and that inhibition of MMP-9 and MMP-2 expression contributes at least in part to the neuroprotection.
Keywords: Nimesulide, neuroprotection, embolic focal cerebral ischemia, thrombolytic reperfusion, matrix metalloproteinases, hemorrhage transformation
Current Neurovascular Research
Title: A Non-Steroidal Anti-Inflammatory Agent Provides Significant Protection During Focal Ischemic Stroke with Decreased Expression of Matrix Metalloproteinases
Volume: 4 Issue: 3
Author(s): Yan Wang, Xiu-Ling Deng, Xiang-Hua Xiao and Bing-Xiang Yuan
Affiliation:
Keywords: Nimesulide, neuroprotection, embolic focal cerebral ischemia, thrombolytic reperfusion, matrix metalloproteinases, hemorrhage transformation
Abstract: The present study was designed to investigate whether the neuroprotective effect of nimesulide was mediated by inhibiting expression of matrix metalloproteinase-9 (MMP-9) and/or matrix metalloproteinase-2 (MMP-2) in a rat model of thrombolytic reperfusion after the embolic focal cerebral ischemia (FCI). It was found that nimesulide at therapeutically relevant doses (3, 6 and 12 mg/kg) decreased neurological deficits, infarct volume, brain index and brain water content in a dose-dependent manner. Hemorrhagic transformation was reduced by 64% with treatment of 12 mg/kg nimesulide. Quantitative analysis of immunohistochemical staining of brain slices showed that the neuron number expressing MMP-9 and MMP-2 increased in the model animals treated with vehicle (p < 0.01 vs sham group), and significantly decreased in nimesulide-treated animals (p < 0.05 or p < 0.01 vs vehicle group). Our results demonstrate that nimesulide significantly reduces the degree of neuronal injury and hemorrhage transformation caused by thrombolytic reperfusion after the embolic FCI, and that inhibition of MMP-9 and MMP-2 expression contributes at least in part to the neuroprotection.
Export Options
About this article
Cite this article as:
Yan Wang , Xiu-Ling Deng , Xiang-Hua Xiao and Bing-Xiang Yuan , A Non-Steroidal Anti-Inflammatory Agent Provides Significant Protection During Focal Ischemic Stroke with Decreased Expression of Matrix Metalloproteinases, Current Neurovascular Research 2007; 4 (3) . https://dx.doi.org/10.2174/156720207781387187
DOI https://dx.doi.org/10.2174/156720207781387187 |
Print ISSN 1567-2026 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5739 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting Kinin Receptors for the Treatment of Neurological Diseases
Current Pharmaceutical Design Oxidative Stress, Endothelial Dysfunction and Atherosclerosis
Current Pharmaceutical Design Role of Heat Shock Proteins in Atherosclerosis and Atrial Fibrillation
Current Immunology Reviews (Discontinued) Dynamic Factors Controlling Targeting Nanocarriers to Vascular Endothelium
Current Drug Metabolism Meet the Editorial Board
Current Drug Targets Tailoring NO Donors Metallopharmaceuticals: Ruthenium Nitrosyl Ammines and Aliphatic Tetraazamacrocycles
Current Medicinal Chemistry New Therapies to Modulate Post-Infarction Inflammatory Alterations in the Myocardium: State of the Art and Forthcoming Applications
Current Radiopharmaceuticals Biological and Pharmacological Activities of Carvacrol and Carvacrol Bearing Essential Oils
Current Pharmaceutical Design Realizing the Potential of Health-Promoting Rosehips from Dogroses (Rosa sect. Caninae)
Current Bioactive Compounds Drug-Induced Thromboembolic Events in Patients with Malignancy
Cardiovascular & Hematological Disorders-Drug Targets Extracellular Vesicles as Novel Delivery Tools for Cancer Treatment
Current Cancer Drug Targets Inhibition of Platelet Glycoprotein Ib and Its Antithrombotic Potential
Current Pharmaceutical Design A Therapeutic Target of Cerebral Hemorrhagic Stroke: Matrix Metalloproteinase- 9
Current Drug Targets NF-κ B and Rheumatic Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Indian Spices for Healthy Heart - An Overview
Current Cardiology Reviews Cardiac Sarcolemmal Ion Channels and Transporters as Possible Targets for Antiarrhythmic and Positive Inotropic Drugs: Strategies of the Past-Perspectives of the Future
Current Pharmaceutical Design Production and Degradation of Oxygen Metabolites During Inflammatory States in the Human Lung
Current Drug Targets - Inflammation & Allergy Beclin 1 Biology and its Role in Heart Disease
Current Cardiology Reviews Nanoparticulated Quercetin in Combating Age Related Cerebral Oxidative Injury
Current Aging Science The Role of Intracellular 35-Cyclic Adenosine Monophosphate (cAMP) in Atherosclerosis
Current Vascular Pharmacology